-
Product Insights
Stomatitis (Sore Mouth) – Drugs In Development, 2023
Global Markets Direct’s, ‘Stomatitis (Sore Mouth) - Drugs In Development, 2023’, provides an overview of the Stomatitis (Sore Mouth) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Stomatitis (Sore Mouth), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Oral Mucositis – Drugs In Development, 2023
Global Markets Direct’s, ‘Oral Mucositis - Drugs In Development, 2023’, provides an overview of the Oral Mucositis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drugs In Development, 2023’, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drugs In Development, 2023’, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Candidiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Candidiasis - Drugs In Development, 2023’, provides an overview of the Candidiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Cystic Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cystic Fibrosis - Drugs In Development, 2023’, provides an overview of the Cystic Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drugs In Development, 2023’, provides an overview of the Clostridioides difficile Infections (Clostridium difficile Associated Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Methicillin-Resistant Staphylococcus Aureus (MRSA) Clinical Trial Report Overview A total of 418 MRSA clinical trials were conducted as of January 2024. The MRSA clinical trial report provides a comprehensive understanding of the MRSA clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       ...